Our advanced kinase
inhibitors are designed
to address the key
limitations of cancer
therapies.
 

Deciphera Pharmaceuticals to Present at 27th Annual Oppenheimer Healthcare Conference

Deciphera Pharmaceuticals, a clinical-stage biopharmaceutical company focused on addressing key mechanisms of tumor drug resistance, today announced that Michael D. Taylor, Ph.D., Deciphera’s President and Chief Executive Officer will present a corporate update at the upcoming 27th Annual Oppenheimer Healthcare Conference at The Westin New York Grand Central in New York City on Tuesday, March 21, 2017 at 2:45 p.m. ET in Track 3.

About Deciphera Pharmaceuticals
Deciphera Pharmaceuticals is a clinical-stage biopharmaceutical company focused on improving the lives of cancer patients by tackling key mechanisms of drug resistance that limit the rate and/or durability of response to existing cancer therapies. Our small molecule drug candidates are directed against an important family of enzymes called kinases, known to be directly involved in the growth and spread of many cancers. We use our deep understanding of kinase biology together with a proprietary chemistry library to purposefully design compounds that maintain kinases in a “switched off’ or inactivated conformation. These therapies comprise tumor-targeted agents designed to address therapeutic resistance causing mutations and immuno-targeted agents designed to control the activation of immunokinases that suppress critical immune system regulators, such as macrophages. We have used our platform to develop a diverse pipeline of tumor-targeted and immuno-targeted drug candidates designed to improve outcomes for patients with cancer by improving the quality, rate and/or durability of their response to treatment.

Contacts:
Christopher J. Morl, Chief Business Officer
Deciphera Pharmaceuticals, LLC
cmorl@deciphera.com
781-209-6418

Media:
Gina Nugent, The Yates Network
gina@theyatesnetwork.com
617-460-3579

Back to Top